Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/64640

Type
Article
Copyright
Restricted access
Embargo date
2200-12-31
Sustainable Development Goals
03 Saúde e Bem-Estar
Collections
Share

Statistics
Metadata
Show full item record

NEW DRUG DISCOVERY STRATEGIES FOR THE TREATMENT OF BENZNIDAZOLE-RESISTANCE IN TRYPANOSOMA CRUZI, THE CAUSATIVE AGENT OF CHAGAS DISEASE
Murta, Silvane Maria Fonseca et al. | Date Issued: 2024
Author
Murta, Silvane Maria Fonseca
Santana, Pedro Augusto Lemos
Lapierre, Thibault Joseph William Jacques Dit
Penteado, André Berndt
Hajje, Marissa El
Vinha, Thabata Corazza Navarro
Liarte, Daniel Barbosa
Souza, Mariana Laureano de
Trossini, Gustavo Henrique Goulart
Rezende Júnior, Celso de Oliveira
Oliveira, Renata Barbosa de
Ferreira, Rafaela Salgado
Affilliation
Fundação Oswaldo Cruz. Instituto René Rachou. Grupo de Genômica Funcional de Parasitos. Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Produtos Farmacêuticos. Belo Horizonte, MG, Brazil.
Universidade Federal de Uberlândia. Instituto de Química. Uberlândia, MG, Brazil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas. Departamento de Farmácia. São Paulo, SP, Brazil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas. Departamento de Farmácia. São Paulo, SP, Brazil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas. Departamento de Farmácia. São Paulo, SP, Brazil.
Universidade Federal do Piauí. Departamento de Biologia. Teresina, PI, Brasil.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brazil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas. Departamento de Farmácia. São Paulo, SP, Brazil.
Universidade Federal de Uberlândia. Instituto de Química. Uberlândia, MG, Brazil.
Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Produtos Farmacêuticos. Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brazil.
Abstract
Introduction: Benznidazole, the drug of choice for treating Chagas Disease (CD), has significant limitations, such as poor cure efficacy, mainly in the chronic phase of CD, association with side effects, and parasite resistance. Understanding parasite resistance to benznidazole is crucial for developing new drugs to treat CD. Areas covered: Here, the authors review the current understanding of the molecular basis of benznidazole resistance. Furthermore, they discuss the state-of-the-art methods and critical outcomes employed to evaluate the efficacy of potential drugs against T. cruzi, aiming to select better compounds likely to succeed in the clinic. Finally, the authors describe the different strategies employed to overcome resistance to benznidazole and find effective new treatments for CD. Expert opinion: Resistance to benznidazole is a complex phenomenon that occurs naturally among T. cruzi strains. The combination of compounds that inhibit different metabolic pathways of the parasite is an important strategy for developing a new chemotherapeutic protocol.
Keywords in Portuguese
Doença de Chagas
benznidazole
interação medicamentosa
formulação medicamentosa
resistência a remedios
 
Keywords
Chagas disease
benznidazole
drug combinations
drug formulations
drug resistance
novel treatments
 
Publisher
Taylor & Francis
Citation
MURTA, Silvane Maria Fonseca et al. New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi, the causative agent of Chagas disease. Expert Opinion on Drug Discovery, v. 19, n. 6, p. 741-753, 2024. doi.org/10.1080/17460441.2024.2349155.
ISSN
1746-0441